Dr Dane Cheasley
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
14 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profiles
DOI: 10.1038/s41523-025-00884-y2026
Journal article
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status
DOI: 10.3390/ijms270417742024
Journal article
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
DOI: 10.1038/s41597-024-03869-x2022
Journal article
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
DOI: 10.1038/s41698-022-00288-22021
Journal article
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects
DOI: 10.1038/s41523-021-00255-32021
Journal article
Phenotypic consequences of slc25a40-abcb1 fusions beyond drug resistance in high-grade serous ovarian cancer
DOI: 10.3390/cancers132256442020
Research grants (ARC, NHMRC, MRFF)
High Throughput Discovery of Synergistic Drug Combinations for Patients With Low-Grade Serous Ovarian Cancer
RECENT SCHOLARLY WORKS
2021
Journal article
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
DOI: 10.1038/s41379-020-0618-92020
Journal article
The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma
DOI: 10.1038/s41523-020-0150-62020
Journal article
Therapeutic options for mucinous ovarian carcinoma
DOI: 10.1016/j.ygyno.2019.12.0152019
Journal article
The molecular origin and taxonomy of mucinous ovarian carcinoma
DOI: 10.1038/s41467-019-11862-x
RECENT PROJECTS
2020
Research grants (ARC, NHMRC, MRFF)
High Throughput Discovery of Synergistic Drug Combinations for Patients With Low-Grade Serous Ovarian Cancer